How much does it cost to take Mobotinib for a month?

Mobocertinib (Mobocertinib), trade name Exkivity, is a third-generation tyrosine kinase inhibitor (TKI) developed by Japan's Takeda Pharmaceutical Co., Ltd. It is specifically designed to treat EGFR (epidermal growth factor receptor) exon 20 insertion mutations in patients with non-small cell lung cancer (NSCLC). This type of mutation often shows resistance to traditional EGFR-TKI drugs, and mobosetinib offers a new treatment option by irreversibly binding to and inhibiting the tyrosine kinase activity of these mutants.

In China, Mobotinib (Mobosetinib) is already on the market, but it has not yet been included in medical insurance, which means that patients need to pay for the drug out of pocket. According to the pricing in the market, the treatment cost of Mobotinib (Mobosetinib) is about RMB 7 to 8,000 per box. This is a significant expense for most patients, so many patients need to carefully consider their financial situation and affordability before purchasing.

In comparison, the prices of foreign generic drugs are relatively cheaper. The price of generic drugs produced in Laos and Bangladesh is about more than 3,000 yuan a month, which is about half of the original drug. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, so they are a more affordable option for patients with heavy financial burdens. However, patients should ensure that they purchase generic drugs through formal channels to ensure the quality and safety of the drugs.

When choosing to purchase Mobotinib (Mobosetinib) , patients should first consult a professional doctor to choose the appropriate drug based on their condition and financial situation. At the same time, when purchasing drugs, make sure to go through regular and trustworthy drug suppliers or pharmacies to avoid buying fake or inferior drugs. Patients should also be aware of the price differences between different versions of the drug so they can make the most appropriate choice.